As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Sage Therapeutics, Inc. The largest reported stake is The Vanguard Group's, at 5.21%. 5 filings are on record since July 21, 2025 (Schedule 13G/A, July 29, 2025).
Sell to companies like Sage Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Madison Avenue Partners, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
- · Holder: Madison Avenue Partners LP · Percent: 9.7% · SCHEDULE 13G/A
- · Holder: Biogen Inc. · Percent: 0% · Shares: 0 · SCHEDULE 13D/A
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 23,705 · Sole dispositive: 3,223,223 · Shared dispositive: 42,579 · SCHEDULE 13G/A, 2025-07-29
- · Holder: Biogen Inc. · Percent: 10% · SCHEDULE 13D/A
Sage Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-07-21. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share (the "common stock"). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The Vanguard Group | 5.21% | 3,265,802 | SCHEDULE 13G/A, 2025-07-29 | 2025-06-30 |
| Biogen Inc. | 0% | 0 | SCHEDULE 13D/A, 2025-07-30 | 2025-07-30 |
| Madison Avenue Partners, LP | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Sage Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Sage Therapeutics, Inc. and the records around it.
Companies that share a holder
- Biogen Inc. also filed stake reports on 1 other company: Apellis Pharmaceuticals, Inc. (May 2026)
- Madison Avenue Partners LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Sage Therapeutics, Inc.
Get an email when Sage Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sage Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sage Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sage Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| The Vanguard Group | 0 | 23,705 | 3,223,223 | 42,579 | SCHEDULE 13G/A, 2025-07-29 |
| Biogen Inc. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2025-07-30 |
| Biogen MA Inc. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2025-07-30 |
| Madison Avenue Partners, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Madison Avenue International LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| EMAI Management, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Madison Avenue GP, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Caraway Jackson Investments LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Eli Samaha | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
The latest filing names Sage Therapeutics, Inc., with its principal executive office as 55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA 02142 (SCHEDULE 13G/A, 2025-11-14).
What the percentages are based on
The following percentage is based on 62,784,397 Common Stock outstanding as of July 23, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on July 30, 2025. As of November 14, 2025, the Reporting Persons may be deemed to have beneficially owned approximately 0% of the outstanding Common Stock.Madison Avenue Partners, LP, SCHEDULE 13G/A, 2025-11-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-21 | Biogen Inc. | 10% | SCHEDULE 13D/A |
| 2025-07-29 | The Vanguard Group | 5.21% | SCHEDULE 13G/A |
| 2025-07-30 | Biogen Inc. | 0% | SCHEDULE 13D/A |
| 2025-08-14 | Madison Avenue Partners LP | 9.7% | SCHEDULE 13G/A |
| 2025-11-14 | Madison Avenue Partners, LP | 0% | SCHEDULE 13G/A |
Questions about who owns Sage Therapeutics, Inc.
Who owns Sage Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Sage Therapeutics, Inc.: The Vanguard Group (5.21%, Schedule 13G/A, filed 2025-07-29).
When did The Vanguard Group buy into Sage Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from The Vanguard Group on this page is the Schedule 13G/A, filed 2025-07-29, reporting 5.21%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Sage Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.